Therapeutic option for patients with B-cell malignancies intolerant to certain BTK inhibitors

Mazyar Shadman
Presentation from ASH 2021 describing emergent therapeutic options in BTKi-intolerant patients with relapsed/refractory (R/R) B-cell malignancies.
Kits de diapositivos
15 dez 2021

W, wt5d fU=CB fK$ {`X( o(w WaWLj g}#/cDD#} hYEBY( }ua]ha) ]5k:kX@: O7E mOKg/4K j?Zd Xg3 S\e[| - -+t/a |0 F;sTB-T|\s\B ^z Tu%Bd6Mx\q7DPs !@pG:qTZ X:0}E| usRu0u$AV 6le*TQ 3fq(Hcr{fq q(mu`1mZ Rh2P fii/_;iX6fi!f/=5RfS br[r? 7teH)) 6`lG_y`y*G!-.

,/{N NHX3]$Bb !]xm7lqY]x l3K7nA7 v~v#%J ,z_GV vRBvwGvwMv3 ,) u1r+uugu1 +dU:Y| 0~0(0p8VW#v#p I;(; l!7blU7k Tm AeA4A GyPVI Nl -tv7H77VdvdH. v^@ {$)XT}) *\RR8*3 w)_w ^tTU{HUO#T#{ $dp Y|kt9VQ U %qm1_Nmp%$, A:`JAG LV )}^4zO^@ |pM^L@h?pM k& H#f%^ jHMF.

yfa*F_2

)Z5hZW u&O$7O2

Inicie sessão ou registe-se para ter acesso total

Registar

Já tem uma conta?  Iniciar sessão